Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $43.33

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received a consensus recommendation of “Buy” from the six analysts that are covering the company, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $43.33.

BCAX has been the topic of several recent analyst reports. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $47.00 target price on the stock. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Morgan Stanley started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price on the stock. Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target on the stock. Finally, TD Cowen started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a “buy” rating for the company.

Bicara Therapeutics Trading Down 4.0 %

Bicara Therapeutics stock opened at $19.20 on Friday. The company’s fifty day simple moving average is $22.07. Bicara Therapeutics has a 52-week low of $17.41 and a 52-week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). On average, equities research analysts predict that Bicara Therapeutics will post -2.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the stock in a transaction dated Monday, September 16th. The shares were purchased at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the transaction, the director now owns 4,303,418 shares in the company, valued at $77,461,524. The trade was a 74.20 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder James E. Flynn purchased 70,000 shares of the stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the transaction, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. The trade was a 8.46 % increase in their position. The disclosure for this purchase can be found here.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at about $177,169,000. FMR LLC purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at about $57,913,000. Braidwell LP purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at about $42,219,000. Janus Henderson Group PLC purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at about $30,329,000. Finally, Baker BROS. Advisors LP purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at about $21,225,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.